Therefore, LBP plus AE can activate AMPK, thereby reducing the expression of hepatic SREBP-1c levels and inhibiting DNL, thereby ameliorating NASH. This evidence concerns the gene SREBF1 and metabolic dysfunction-associated steatohepatitis.